• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Recent Advances in the Study of Bicyclo[3.3.1]nonan-3-one (CAS: 10036-09-6) and Its Applications in Chemical Biology and Medicine

Bicyclo[3.3.1]nonan-3-one (CAS: 10036-09-6) is a structurally unique bicyclic ketone that has garnered significant attention in recent years due to its versatile applications in chemical biology and medicinal chemistry. This compound, characterized by its rigid bicyclic framework, serves as a valuable scaffold for the synthesis of bioactive molecules and has been explored for its potential in drug discovery and development. Recent studies have focused on elucidating its chemical properties, synthetic methodologies, and biological activities, providing new insights into its utility in pharmaceutical research.

One of the key areas of research involving bicyclo[3.3.1]nonan-3-one is its role as a building block for the synthesis of complex natural products and pharmacologically active compounds. A 2023 study published in the Journal of Organic Chemistry demonstrated an efficient synthetic route to functionalized derivatives of this compound, highlighting its potential as a precursor for the development of novel therapeutics. The study employed advanced catalytic methods, including asymmetric hydrogenation, to achieve high enantioselectivity, which is critical for the production of chiral drugs.

In addition to its synthetic utility, bicyclo[3.3.1]nonan-3-one has been investigated for its biological activities. Recent findings published in Bioorganic & Medicinal Chemistry Letters revealed that certain derivatives of this compound exhibit promising antimicrobial and anti-inflammatory properties. These derivatives were shown to inhibit key enzymes involved in bacterial cell wall synthesis and inflammatory pathways, suggesting their potential as leads for new antibiotic and anti-inflammatory drugs. The study also emphasized the importance of structural modifications to enhance bioavailability and reduce toxicity.

Another notable advancement is the application of bicyclo[3.3.1]nonan-3-one in the design of enzyme inhibitors. A 2024 study in ChemMedChem reported the development of bicyclo[3.3.1]nonan-3-one-based inhibitors targeting the SARS-CoV-2 main protease. The researchers utilized molecular docking and dynamics simulations to optimize the interactions between the inhibitor and the protease active site, resulting in compounds with nanomolar affinity. This work underscores the potential of bicyclo[3.3.1]nonan-3-one derivatives in addressing emerging viral threats.

Despite these promising developments, challenges remain in the practical application of bicyclo[3.3.1]nonan-3-one derivatives. Issues such as scalability of synthesis, metabolic stability, and off-target effects need to be addressed to translate these findings into clinically viable therapeutics. Future research directions may include the exploration of novel synthetic strategies, such as biocatalysis or flow chemistry, to improve efficiency and sustainability. Additionally, further in vivo studies are required to validate the efficacy and safety of these compounds in animal models and human trials.

In conclusion, bicyclo[3.3.1]nonan-3-one (CAS: 10036-09-6) represents a promising scaffold in chemical biology and medicinal chemistry, with recent studies highlighting its potential in drug discovery and enzyme inhibition. Continued research efforts are expected to unlock new applications and overcome existing limitations, paving the way for the development of innovative therapeutics. This brief provides a snapshot of the current state of research and underscores the importance of interdisciplinary collaboration in advancing this field.

• 823-76-7(1-cyclohexylethan-1-one)
• 40649-36-3(4-propylcyclohexan-1-one)
• 5441-51-0(4-ethylcyclohexan-1-one)
• 10458-14-7(Menthone)
• 2979-19-3(3,3-dimethylcyclohexan-1-one)
• 61203-83-6(4-Pentylcyclohexanone)
• 700-58-3(Adamantanone)
• 583-60-8(2-Methylcyclohexanone)
• 98-53-3(4-tert-butylcyclohexan-1-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)